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This past month PLoS Medicine pub-
lished two original analyses on smoking,
the single greatest preventable risk for
poor health and death in the developed
world, and an increasingly important risk
factor in the developing world. The first
study, using internal tobacco company
documents unsealed through litigation,
provides further evidence of the already
well-documented strategy of deception
used by the tobacco industry to further
its commercial activities. The second study
shows the ways in which the tobacco
control agenda is distorted by the increas-
ing medicalization of smoking cessation.
In the first paper, Katherine Smith and
colleagues report how British American
Tobacco (BAT), the world’s second largest
tobacco transnational, strategically influ-
enced the European Union’s framework
for evaluating policy options, leading to the
acceptance of an agenda that emphasizes
business interests over public health [1].
The researchers examined over 700 inter-
nal BAT documents that contain informa-
tion on the company’s attempts to influence
European regulatory reform and conducted
interviews with European policymakers and
lobbyists. Their analyses show that BAT
created a policy network of representatives
from many corporations involved in mar-
keting products that are damaging to public
health and the environment, which then
successfully campaigned to have specific
changes made to the EU Treaty that
allowed policymakers to reduce the regula-
tory burden on businesses. These changes
therefore set up conditions that may allow
future European policy to favor businesses
rather than the health of citizens.
In the second paper, Simon Chapman
and Ross MacKenzie critique the domi-
nant messages about smoking cessation
contained in most tobacco control cam-
paigns, which emphasize that serious
attempts at quitting smoking must be
pharmacologically or professionally medi-
ated [2]. This has led to the medicalization
of smoking cessation. In fact, argue the
authors, there is good evidence that the
most successful methods used by most ex-
smokers are quitting ‘‘cold turkey’’ or
reducing then quitting. The medicaliza-
tion of smoking cessation is propped up by
the extent and influence of pharmaceutical
support for cessation intervention studies,
say the authors. They cite a recent review
of randomized controlled trials of nicotine
replacement therapy that found that 51%
of industry-funded trials reported signifi-
cant cessation effects, while only 22% of
non-industry trials did [3].
This month also marks the implemen-
tation of a new policy on tobacco papers at
PLoS Medicine.
W h i l ew ec o n t i n u et ob ei n t e r e s t e di n
analyses of ways of reducing tobacco use,
we will no longer be considering papers
where support, in whole or in part, for the
study or the researchers comes from a
tobacco company. As a medical journal we
do this for two reasons. First, tobacco is
indisputably bad for health. Half of all
smokers will die of tobacco use [4]. Unlike
the food and pharmaceutical industries, the
business of tobacco involves selling a
product for which there is no possible
health benefit. Tobacco interests in research
cannot have a health aim—if they did,
tobacco companies would be better off
shutting down business—and therefore
health research sponsored by tobacco
companies is essentially advertising. Publi-
cation is part of tobacco company market-
ing, and we believe it would be irrespon-
sible to act as part of the machinery that
enhances the reputation of an industry
producing health-harming products.
Second, we remain concerned about the
industry’s long-standing attempts to distort
the science of and deflect attention away
from the harmful effects of smoking. That
the tobacco industry has behaved disrep-
utably—denying the harms of its products,
campaigning against smoking bans, mar-
keting to young people, and hiring public
relations firms, consultants, and front
groups to enhance the public credibility
of their work—is well documented. There
is no reason to believe that these direct
assaults on human health will not contin-
ue, and we do not wish to provide a forum
for companies’ attempts to manipulate the
science on tobacco’s harms.
Furthermore, the business model used
to support our open access publishing (the
research funder covers publication costs,
unless the author requests a waiver) means
we would essentially be accepting money
from the tobacco industry by publishing
their papers. This is unacceptable to the
editorial team of PLoS Medicine.
Our new policy may be criticized as
moralistic, unscientific, and against trans-
parency. Indeed, the leading tobacco
control journal (Tobacco Control) does not
ban tobacco industry–funded research, for
two reasons: it wishes to avoid being
labeled as biased by the industry, and it
does not think it sensible to single out
tobacco when the food and drug industries
also have deeply vested and conflicted
interests in the research supporting their
corporate agendas [5]. Journals such as
BMJ have also rejected a ban on research
papers from authors funded by the
tobacco industry, citing such a move as a
form of unacceptable censorship and
instead managing the potential competing
interests as it would all papers [6]. Ten
years ago, one of us (GY) argued for the
BMJ position [7], but has changed his
view over the last decade in the face of
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try’s distortion of science.
But other journals such as those of the
American Thoracic Society do have such
policies—since 1995 they have not accept-
ed any medical research that is funded by
the tobacco industry, and they explicitly
do so on moral and ethical grounds [8].
Like the two other PLoS journals that
have recently adopted this policy, PLoS
Biology and PLoS ONE, we feel that any
potential criticisms and risks are preferable
to supporting the tobacco industry’s efforts
to deflect attention from the harms of its
products. It is the case that we do not
receive many tobacco industry sponsored
papers—PLoS Medicine has published none
since our inception in 2004 and PLoS ONE
only two—and we have made previous
editorial judgments on papers that might be
favorable to the tobacco industry agenda on
a case-by-case basis [9]. We wish now to
formalize our policy effective immediately.
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